BioLargo, Inc. Share Price OTC Bulletin Board
Equities
US09065A1007
Commodity Chemicals
End-of-day quote
Other stock markets
|
||
- USD | - |
06-11 | BioLargo, Inc. Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-Ion | CI |
05-14 | Transcript : BioLargo, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Sales 2024 * | 19.05M 1.5B | Sales 2025 * | 25.76M 2.03B | Capitalization | 84.71M 6.68B |
---|---|---|---|---|---|
Net income 2024 * | -1M -78.85M | Net income 2025 * | - 0 | EV / Sales 2024 * | 4.45 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.29 x |
P/E ratio 2024 * |
-28.5
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
Latest transcript on BioLargo, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Dennis Calvert
CEO | Chief Executive Officer | 61 | 31/05/02 |
Charles Dargan
DFI | Director of Finance/CFO | 68 | 31/01/08 |
Chief Operating Officer | 55 | 31/05/02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Marshall
BRD | Director/Board Member | 81 | 27/04/06 |
Kenneth Code
CTO | Chief Tech/Sci/R&D Officer | 77 | 31/03/07 |
Dennis Calvert
CEO | Chief Executive Officer | 61 | 31/05/02 |
1st Jan change | Capi. | |
---|---|---|
-0.52% | 98.24B | |
-10.90% | 58.77B | |
+63.33% | 45.23B | |
+12.56% | 37.42B | |
-1.62% | 30.46B | |
+7.05% | 19.26B | |
+11.98% | 16.67B | |
+6.45% | 13.6B | |
-6.76% | 12.73B |